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Summary 
The molecular basis of signal-dependent transcriptional activation has been 
extensively studied in macrophage polarization, however our understanding remains 
limited regarding the molecular determinants of repression. Here we show that IL-4-
activated STAT6 transcription factor is required for the direct transcriptional repression 
of a large number of genes during in vitro and in vivo alternative macrophage 
polarization. Repression results in decreased lineage-determining transcription factor, 
p300 and RNA polymerase II binding followed by reduced enhancer RNA expression, 
H3K27 acetylation and chromatin accessibility. The repressor function of STAT6 is 
HDAC3-dependent on a subset of IL-4-repressed genes. In addition, STAT6-repressed 
enhancers show extensive overlap with the NF-κB p65 cistrome and exhibit decreased 
responsiveness to lipopolysaccharide after IL-4 stimulus on a subset of genes. As a 
consequence, macrophages exhibit diminished inflammasome activation, decreased 
IL-1ȕ production and pyroptosis. Thus, IL-4-STAT6 signaling pathway establishes an 
alternative polarization-specific epigenenomic signature resulting in dampened 
macrophage responsiveness to inflammatory stimuli. 
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Introduction 
 
Macrophage plasticity is ensured by dynamic and partially reversible responsiveness 
to pathogen-derived molecules as well as the cytokine and lipid microenvironment. The 
two well-characterized extreme functional outcomes of macrophage polarization are T 
helper 1 (Th1) cell-type cytokine interferon gamma (IFNȖ)-induced classical or 
M(INFȖ)-type polarization with enhanced bactericidal capacity and Th2 cell-type 
cytokine interleukin-4 (IL-4)-induced alternative or M(IL-4)-type polarization with anti-
inflammatory properties, but complex molecular cues can generate an entire spectrum 
of different activation states (Gordon and Martinez, 2010; Murray et al., 2014). 
The major determinant of macrophage plasticity is their specific transcriptional program 
dictated primarily by lineage-determining transcription factors (LDTFs) including ETS-
domain transcription factor PU.1, CCAAT/enhancer binding proteins (C/EBPs), 
activator protein 1 (AP-1) or Runt-related transcription factor 1 (RUNX1) as well as 
extracellular signal-dependent transcription factors (SDTFs) among others LPS-
activated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) or AP-
1, IFNȖ-activated signal transducer and activator of transcription 1 (STAT1) or IL-4 and 
IL-13-activated STAT6; for a review see (Glass and Natoli, 2016). Despite the fact that 
polarization signals repress large sets of genes, the repressive activity of polarization-
specific transcription factors has not been studied in detail (Bhatt et al., 2012; Martinez 
et al., 2013). Recently, a whole new spectrum of next-generation sequencing-based 
methods has evolved enabling the characterization of the molecular features of 
transcriptional repression in macrophages at an unprecedented level (Hah et al., 2015; 
Kang et al., 2017). 
IL-4 or IL-13-induced alternative macrophage polarization occurs in a number of 
pathological processes including nematode infection, tumor development, lung 
inflammation and fibrosis (Gordon and Martinez, 2010). Given the complex 
immunological milieu that characterizes each of these conditions, alternatively 
polarized macrophages are likely to encounter inflammatory stimuli as well (Fort et al., 
2001; Ruffell et al., 2012). It has been shown that in vitro modeling of complex 
immunological microenvironment by IL-4 and IFNȖ co-stimulation leads to the 
attenuation of IFNȖ-induced transcriptional activation due to the effects of IL-4 on 
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restrictive set of auxiliary transcription factors in mouse macrophages (Piccolo et al., 
2017). These results suggest that alternatively polarized macrophages exhibit an 
altered responsiveness to inflammatory signals. The underlying crosstalk at the 
epigenomic and transcriptional levels remain largely unexplored. One of the effector 
functions of macrophages is the integration of different danger signals with NLRP3 
inflammasome activation (Rathinam and Fitzgerald, 2016). Inflammasomes play key 
roles in the generation of proinflammatory secreted forms of IL-1ȕ and IL-18 from their 
precursors. In parallel, macrophages undergo active NLRP3 inflammasome-
dependent cell death termed "pyroptosis" (Rathinam and Fitzgerald, 2016). The 
integration of this process to inflammatory epigenomic signaling is also not known. 
We sought to address these questions regarding the integration and regulation of the 
alternatively polarized macrophage phenotype by carrying out systemic genome-wide 
studies. 
 
Results 
 
IL-4 induces transcriptional activation and repression via STAT6 
 
We determined the STAT6-dependent IL-4-regulated genes in a time course in wild-
type (WT) and Stat6-/- bone marrow-derived macrophages (BMDMs) using RNA-seq 
(Figure S1A). First, we examined the gene expression pattern of the 1614 IL-4-
regulated genes (Fc≥β, p-value<0.05) and identified four IL-4-induced gene expression 
clusters based on expression dynamics and fold induction (Figure 1A, Figure S1B and 
Supplemental Table 1). We also found that a high portion of IL-4-responsive genes 
(39%) was repressed. Repression by IL-4 was observed after 3 hours and remained 
attenuated at later time points (6, 24h) (Figure 1A, Cluster E and Supplemental Table 
1). IL-4-mediated repression is dependent on STAT6 (Figure 1B). For validation, we 
measured the mRNA level of six IL-4-repressed (Abca1, Clec4d, Fos, Tlr2, Cd14 and 
Nlrp3) and three activated (Klf4, Hbegf and Edn1) genes with RT-qPCR, and confirmed 
IL-4-mediated and STAT6-dependent regulation (Figure 1C and Figure S1C). 
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Filarial nematode infection is associated with the accumulation of M2 macrophages, 
exhibiting elevated expression of Ym1 and Fizz1/RELM-α (Anthony et al., 2006). In 
order to determine whether transcriptional repression in response to M2-polarizing 
signals occurs in vivo, we compared the gene expression profile of peritoneal 
macrophages from Brugia malayi nematode-implanted mice (Ne-Mac) and 
thioglycollate-elicited peritoneal macrophages (Thio-Mac) utilizing publicly available 
RNA-seq data (Thomas et al., 2012). Gene Set Enrichment Analysis (GSEA) analysis 
showed that the in vitro IL-4-repressed gene set was significantly enriched (FDR q-
value<0.1, NER: -2.38) among the genes that were down-regulated in response to 
nematode infection in peritoneal macrophages (Figure 1D). In addition, all selected IL-
4-STAT6-repressed genes were significantly down-regulated during Brugia malayi-
induced in vivo alternative macrophage polarization compared to thioglycollate-elicited 
peritoneal macrophages (Figure 1E). 
Next, we determined whether IL-4-STAT6 signaling represses gene expression at the 
transcriptional or post-transcriptional level. We assessed the immediate early effect of 
IL-4 on two serine phosphorylated forms of RNA polymerase II, the active histone mark 
H3K27Ac and nascent RNA expression by GRO-seq after 1 hour of exposure. 
Elongation-specific RNAPII-pS2 ChIP-seq revealed 5931 gene bodies, exhibiting 
significantly changing read enrichments (3008 down-regulated and 2923 up-regulated, 
p≤0.1) (Figure SβA and Supplemental Table 2). RNAPII-pS2 binding showed positive 
correlation with transcription initiation-specific RNAPII-pS5 binding, H3K27Ac 
enrichment and nascent RNA expression at the gene bodies (Figure S2B). Importantly, 
the gene bodies of IL-4 repressed genes (Cluster E) showed attenuated RNAPII-pS2, 
RNAPII-pS5 and H3K27Ac enrichment and nascent RNA expression (Figure 2A, B and 
Figure S2C). In contrast, IL-4-dependent induction of RNAPII-pS2, RNAPII-pS5 and 
H3K27Ac enrichment as well as nascent RNA expression was detected at gene bodies 
of IL-4-induced genes (Cluster A-C) (Figure 2A, Figure S2C and D). These results 
indicate that IL-4-STAT6 signaling directly represses gene expression, primarily at the 
transcriptional level during alternative macrophage polarization in vitro and in vivo. 
 
IL-4-activated STAT6 binding is required for transcriptional repression 
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We also determined the STAT6 cistrome using a time course of 1, 6 and 24 hours of 
IL-4 stimulation (Figure S1A). STAT6 binding was negligible in unstimulated BMDMs 
(Figure 3A), but as short as 1 hour of stimulation dramatically induced the binding of 
STAT6, which was followed by a decline after 24 hours (Figure 3A). Comparing the 
STAT6 cistrome (20119 genomic regions in IL-4-stimulated cells) to the RNAPII-pS5 
positive genomic regions revealed that 60.5% of STAT6 peaks overlapped with the 
union of those genomic regions bound by RNAPII-pS5 in resting or IL-4-treated 
BMDMs (Figure 3B), suggesting that transcription could be directly regulated by 
STAT6 at these sites. Thus next, we classified the RNAPII-pS5 positive STAT6 peaks 
based on IL-4-dependent regulation of RNAPII-pS5 binding, and divided the STAT6-
bound genomic regions into three different clusters: "repressor", "neutral" and 
"activator" STAT6 peak clusters (Figure 3C and Supplemental Table 3). We noted that 
“repressor” and "neutral" STAT6 peaks showed typically lower occupancies if 
compared to the IL-4-induced RNAPII-pS5-associated "activator" STAT6 peaks 
(Figure S3A). Interestingly, IL-4-dependent regulation of RNAPII-pS2 binding as well 
as H3K27Ac enrichments showed similar patterns to RNAPII-pS5 in all three STAT6 
clusters (Figure 3C and D). These findings support the conclusion that IL-4-activated 
STAT6 can be associated with either transcriptional activation or repression at different 
genomic loci. 
Next we assigned STAT6-bound genomic regions to genes in order to assess the 
correlation between IL-4-repressed enhancer activity (RNAPII-pS5 - ChIP-seq) and 
gene expression (mRNA – RNA-seq). For this analysis, we predicted the sub-
topologically associated domains (subTADs) in which gene regulation by STAT6 might 
take place, using CTCF and RAD21 ChIP-seq data sets from BMDM, utilizing a 
previously described algorithm (Daniel et al., 2014; Rao et al., 2014). As shown in 
Figure 3E, we found that "repressor" STAT6 peaks were tightly associated with the IL-
4-repressed gene cluster (Cluster E). In contrast, "activator" STAT6 peaks were 
associated with the immediate early IL-4-induced genes represented by Clusters A-C 
(Figure 3E). These results suggest a tight connection between STAT6-dependent 
regulation of enhancer activity and neighboring gene expression in the same genomic 
compartment or transcription unit. 
To understand the IL-4-STAT6 signaling-mediated transcriptional regulation in more 
detail, we carried out analyses on individual genes and enhancers. For the selected 
 8 
repressed and activated genes we identified at least one STAT6-bound enhancer 
showing reduced and induced H3K27 acetylation and RNAPII binding, respectively 
(Figure 3F). Enhancer RNA (eRNA) expression is a reliable marker of enhancer activity 
(Natoli and Andrau, 2012). Therefore, we measured eRNA expression at the 
"repressor" and "activator" STAT6 peaks by RT-qPCR. The expression of eRNAs were 
regulated in a similar manner as the enrichment of RNAPII-pS5, RNAPII-pS2 and 
changes of H3K27Ac levels at the "repressor" and "activator" STAT6 sites in WT 
BMDMs (Figure 3F and G, Figure S3B). Importantly, IL-4-mediated regulation of eRNA 
expression was abolished in the absence of STAT6 at the examined enhancers (Figure 
3G and Figure S3B). Taken together, these results show that IL-4-activated STAT6 is 
required for the transcriptional repression characterized by decreasing RNAPII binding, 
histone acetylation and consequently enhancer activity. 
 
STAT6 binds to repressed sites in the absence of a canonical binding motif 
 
In order to investigate whether the functional characteristics of STAT6 peaks 
(“activator” vs. “repressor”) are influenced by their genomic localization and/or the DNA 
sequences they are associated with, we analyzed the genomic distribution of STAT6 
peak clusters. We found only minor differences between the distinct STAT6 peak 
clusters regarding genomic localization relative to genes (Supplemental Table 4). The 
majority of STAT6 peaks were localized in intergenic and intronic regions in the 
genome in all three clusters, and only about 10% of STAT6 binding sites were detected 
in promoter-proximal regions (Supplemental Table 4). We also examined the 
enrichment of active histone mark H3K4m1 at the STAT6-bound genomic regions 
using a publicly available ChIP-seq data set (Ostuni et al., 2013). Although H3K4m1 
enrichment was observed at more than 98% of STAT6-bound genomic regions, it was 
not influenced by IL-4 treatment (Supplemental Table 4, Figure S3C). These findings 
suggest that STAT6 primarily binds enhancers and the functional characteristics of 
different STAT6 peak clusters cannot be explained by their genomic localization 
relative to genes. 
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Next, we carried out de novo motif enrichment analysis of the sequences under the 
STAT6 peaks. PU.1, TRE, RUNX and CEBP motifs were enriched under all three 
clusters (Figure S3D). However, the canonical STAT6 motif was significantly under-
represented under "repressor" and "neutral" STAT6 peaks if compared to the 
"activator" STAT6 peaks (Figure 3H and Figure S3D). Plotting the motif scores for 
PU.1, TRE, RUNX and CEBP revealed no significant differences between the different 
STAT6 peak clusters (Figure S3E). In contrast, motif score for STAT6 was lower in the 
“repressor” and "neutral" STAT6 peak clusters compared to the “activator” STAT6 peak 
cluster (Figure 3I). Considering that the presence of STAT6 is needed for repression 
(Figure 1B), these findings raise the possibilities that STAT6 is bound without direct 
DNA contact or it recognizes non-canonical STAT6-binding motifs at repressed 
enhancers. 
 
STAT6-mediated repression of enhancer activity is accompanied by decreased 
chromatin accessibility and lineage-determining transcription factor binding 
 
We investigated whether chromatin accessibility is affected at the STAT6-bound 
genomic regions by performing ATAC-seq experiments. Our genome-wide analyses 
showed increased chromatin accessibility at the “activator” STAT6-bound sites (Figure 
4A), while significant reduction was detected in chromatin accessibility at the 
“repressor” STAT6-bound genomic regions (Figure 4A). These results suggest that 
both STAT6-mediated enhancer activation and repression are associated with the 
modification of chromatin structure during alternative macrophage polarization. 
Chromatin openness determines enhancer activity in different cell types (Shlyueva et 
al., 2014). Moreover, binding of macrophage LDTFs, PU.1, JUNB, IRF8 and C/EBPα 
are associated with active enhancers in macrophages (Glass and Natoli, 2016). In 
addition, their binding motifs were amongst the most enriched transcription factor 
motifs under STAT6 peaks (Figure S3D). Therefore, we decided to determine whether 
IL-4-STAT6 signaling-mediated repression is associated with modified binding of 
LDTFs and examined their binding at repressed enhancers in the presence or absence 
of IL-4 using ChIP-seq. A high portion of the STAT6 cistrome overlapped with the 
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examined LDTF cistromes except for JUNB, which showed moderated overlap 
(Supplemental Table 4). Intriguingly, PU.1, JUNB and C/EBPα binding was 
significantly decreased, while IRF8 binding was not modulated at the repressed 
STAT6-bound genomic regions after 1 hour IL-4 treatment in BMDMs (Figure 4B and 
Figure S4A). In contrast, all four LDTFs showed significantly elevated binding at the 
IL-4-activated enhancers following IL-4 stimulation (Figure 4B and Figure S4A). These 
findings suggest that IL-4-STAT6 signaling pathway modulates the binding of LDTFs 
at STAT6-activated and repressed enhancers to opposite directions. 
 
IL-4-STAT6 signaling pathway-mediated repression of enhancers is 
characterized by an altered p300:HDAC ratio 
 
The acetylation status and thus the activity of enhancers are tightly controlled by 
histone acetyltransferase (HAT) and histone deacetylase (HDAC) enzymes (Calo and 
Wysocka, 2013). Therefore, we examined the binding of the histone acetyltransferase 
p300 as well as classical histone deacetylases, including HDAC1, 2 and 3 at the 
STAT6-bound genomic regions after 1 hour of IL-4 exposure by ChIP-seq. We found 
that the majority of STAT6-bound genomic regions were either pre-loaded by p300 and 
classical HDACs or recruited these factors upon IL-4 stimulation (Supplemental Table 
4). The binding of p300 was significantly increased at STAT6-activated enhancers, but 
significantly reduced at STAT6-repressed enhancers upon IL-4 treatment (Figure 4C). 
Interestingly, genome-wide analysis of IL-4-modulated HDAC binding showed 
significantly enhanced HDAC1, 2 and 3 occupancy at STAT6-activated enhancers, 
while STAT6-repressed enhancers showed no effect to IL-4, but exhibited HDAC 
binding at the basal state (Figure 4D). Collectively, these results show that STAT6-
repressed enhancers are bound by both HATs and HDACs at the steady-state, and 
p300 binding is selectively reduced by IL-4, resulting in a changed equilibrium favoring 
HDAC activity. 
 
The presence of HDAC3 is required for IL-4-STAT6-mediated repression on a 
subset of genes 
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Direct interactions between classical HDACs and STAT transcription factors have been 
observed previously in numerous cell types influencing STAT-mediated direct 
transcriptional regulation (Icardi et al., 2012; Nusinzon and Horvath, 2003). In addition, 
HDAC3 has been shown to participate in the regulation of alternative macrophage 
polarization in vitro and in vivo (Mullican et al., 2011). Thus, we hypothesized that 
HDAC3, which is present at repressed enhancers, (Figure 4D), might also contribute 
to IL-4-STAT6-induced repression. Therefore, we decided to examine the role of 
HDAC3 using a dataset from Mullican et al. (Mullican et al., 2011). Applying K-mean 
clustering method, we found 1628 IL-4-repressed genes (p≤0.05) in WT BMDMs 
(Figure S4B) and identified an IL-4-repressed gene cluster (Cluster III., 371 genes), 
which showed attenuated repression in HDAC3fl/fl Lyz2 Cre BMDMs following IL-4 
treatment (Figure 4E and Figure S4B). Although the basal expression of these genes 
did not show major differences between WT and HDAC3fl/fl Lyz2 Cre BMDMs, the IL-
4-induced repression was partially or completely abolished in the absence of HDAC3 
(Figure 4E and Figure S4B). In addition, enrichments of RNAPII-pS5 and RNAPII-S2 
were reduced at these gene bodies after 1 hour of IL-4 treatment in WT BMDMs (Figure 
4F). Interestingly, 325 STAT6-repressed enhancers were found within the subTADs of 
IL-4-HDAC3-repressed genes (Figure 4G). These enhancers were bound by HDAC3, 
but HDAC3 occupancy was not altered by IL-4 stimulation (Figure 4G and H). Our 
results indicate that HDAC3 is required for the IL-4-induced repression of a specific 
subset of genes. 
Due to the fact that HDAC3 is one of the key components of NCoR and SMRT 
corepressor complexes (Karagianni and Wong, 2007), we decided to determine 
whether the NCoR-SMRT complex itself participates in IL-4-STAT6-HDAC3-mediated 
repression as well. First, we determined the occupancy of NCoR and SMRT at HDAC3-
bound enhancers using ChIP-seq data generated by others (Barish et al., 2012). We 
found that the IL-4-STAT6-HDAC3-repressed enhancer set was bound by both NCoR 
and SMRT in unstimulated BMDMs (Figure 4G). Next, we investigated the requirement 
of NCoR in the IL-4-STAT6-HDAC3-mediated repression using NCoRfl/fl Lyz2 Cre 
immortalized bone marrow-derived macrophages (iBMDMs). We selected four genes 
for this analysis, including Fos, Lyz1, Lyz2 and Smad3 based on their IL-4-STAT6-
HDAC3-dependent repression (Figure 4I and Figure S4C and D) and due to the fact 
that their enhancers were bound by HDAC3, NCoR and SMRT (Figure S4C). Gene 
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expression analysis showed that Fos and Lyz1 genes were expressed at a significantly 
higher level in unstimulated iBMDMs in the absence of NCoR compared to WT 
iBMDMs, while the basal expression of Lyz2 and Smad3 were not affected by NCoR 
(Figure 4J). In addition, IL-4-mediated repression of these genes was diminished in 
NCoRfl/fl Lyz2 Cre iBMDMs (Figure 4J and Figure S4E). In contrast, the basal 
expression and IL-4-induced repression of HDAC3-independent genes were not 
affected by NCoR, except for Abca1 (Figure S4F). Taken together, our findings suggest 
that IL-4-activated STAT6 mediates transcriptional repression via the NCoR-HDAC3 
complex at a subset of genes representing one of the molecular mechanisms for 
STAT6-dependent transcriptional repression. 
 
IL-4-STAT6-mediated direct transcriptional repression affects the LPS-induced 
inflammatory program of macrophages 
Next we were wondering whether the repressive action of IL-4-STAT6 leaves its 
footprint on the epigenome and affects the subsequent response of the cells to other 
stimuli. Using KEGG pathway analysis, we identified twelve signaling pathways whose 
overrepresentation was specific to IL-4-repressed genes (Figure S5A). NOD-like 
receptor signaling and Toll-like receptor signaling w among the top hits, which are 
known to be two major regulators of the inflammatory response (Figure S5A) (Chen et 
al., 2009; Takeda et al., 2003). In addition, upstream transcriptional regulator analysis 
with Ingenuity Pathway Analysis (IPA) software revealed that, the LPS-activated p65 
(RelA) is one of the most significantly inhibited transcriptional regulators upon IL-4 
stimulation (Figure S5B). Interestingly, the majority of IL-4-STAT6-repressed genes 
included several members of NOD-like and Toll-like receptor signaling pathways 
showing attenuated mRNA expression following 24 hours of IL-4 stimulation and 
reduced STAT6 binding at the repressed enhancers (Figure 1A and B, Figure S5C and 
D). These results raised the possibility that IL-4 is able to modulate the subsequent 
inflammatory response of the macrophage epigenome via directly repressed 
enhancers following the dissociation of STAT6. 
In order to determine whether prior activation of IL-4-STAT6 signaling is able to 
influence the inflammatory program of macrophages, we performed RNA-seq as well 
as RNAPII-pS5, RNAPII-pS2 and p65-specific ChIP-seq experiments on IL-4-
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pretreated and LPS-activated BMDMs (Figure 5A). Our global transcriptome analysis 
identified 1350 LPS-activated genes (p≤0.05) in BMDMs (Figure 5B, Supplemental 
Table 5). Intriguingly, 5β0 genes showed significantly attenuated (p≤0.05) LPS 
responsiveness following IL-4 pretreatment including the above examined Tlr2, Cd14, 
Clec4d and Nlrp3 (Figure 5B, Supplemental table 5). In addition, LPS-mediated 
induction of 686 genes was not influenced significantly by IL-4 pretreatment, while 144 
genes showed significantly elevated LPS-activation in IL-4-pretreated BMDMs (Figure 
5B and Supplemental Table 5), suggesting that the interaction between the two 
pathways is not a general interference or attenuation, but it takes place on selective 
genomic regions. Interestingly, six out of twelve IL-4-repressed signaling pathways 
were also significantly overrepresented among the genes that were less induced by 
LPS following IL-4 pretreatment, including NOD-like receptor and Toll-like receptor 
signaling pathways (Figure S5E). Next, we investigated whether IL-4-STAT6 signaling 
modulates LPS-dependent activation of inflammatory genes at the transcriptional or 
post-transcriptional level. We examined the IL-4 and LPS-regulated binding of RNAPII-
pS2 at the gene bodies of LPS-induced genes using ChIP-seq. RNAPII-pS2 binding 
showed a similar pattern to “steady-state” mRNA level in all three gene expression 
clusters, suggesting that IL-4 pretreatment modulates LPS-induced gene expression 
primarily at the transcriptional level (Figure 5C). In order to investigate whether the IL-
4-attenuated inflammatory response is STAT6-dependent, we measured the 
expression of Tlr2, Cd14, Clec4d and Nlrp3 genes in WT and Stat6-/- BMDMs after 24 
hours of IL-4 pretreatment followed by 3 hours of LPS-activation. As expected, IL-4 
pretreatment failed to inhibit the LPS response of these genes in the absence of STAT6 
(Figure 5D), raising the possibility that IL-4-activated STAT6 can directly modulate LPS 
responsiveness in macrophages via transcriptional repression of certain components 
of the inflammatory program. 
To determine whether the crosstalk between IL-4-STAT6 signaling and inflammation-
activated signaling pathways can also be observed at the enhancer level, we 
compared the IL-4-activated STAT6 and LPS-activated p65 cistromes in the subTADs 
of IL-4-attenuated LPS-responsive genes. 961 genomic regions were identified with 
overlapping STAT6 and p65 peaks revealing a partial overlap between the STAT6 and 
p65 cistromes (Figure 6A and B). Next, we decided to investigate whether IL-4-STAT6 
and inflammatory signaling pathways are able to interact with each other using RNAPII-
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specific ChIP-seq analysis. 641 out of 961 genomic regions were associated with 
significantly elevated RNAPII-binding following LPS activation (Figure 6B). Intriguingly, 
70% (448/641) of LPS-activated enhancers showed significantly reduced basal and 
LPS-induced RNAPII binding following 24 hours of IL-4 pretreatment (Figure 6B, C, D 
and F). To further explore the mechanism of IL-4-STAT6-attenuated inflammatory 
responsiveness, we determined LPS-induced p65 binding at this enhancer set in IL-4-
pretreated and unstimulated BMDMs. Based on p65 binding, we could identify two 
subsets of these enhancers including IL-4-insensitive and IL-4-attenuated p65 binding-
associated enhancers (Figure 6E and F). LPS-induced p65 binding was significantly 
reduced at 74 IL-4-repressed enhancers, while IL-4-repressed inflammatory response 
was not associated with modulated p65 binding at 374 enhancers (Figure 6E and F). 
To investigate the STAT6-dependency of IL-4-repressed enhancer activity and p65 
binding, we selected three enhancers for both analysis. RT-qPCR-based eRNA 
expression analysis confirmed IL-4-mediated and STAT6-dependent repression of 
basal and LPS-induced activity at the selected enhancers (Figure S6A). By performing 
ChIP-qPCR on the selected IL-4-reduced p65 binding-associated enhancers, we 
confirmed that IL-4-dependent reduction of LPS-induced p65 binding was completely 
abolished in the absence of STAT6 (Figure S6B). 
Taken together, these findings suggest that the activation of IL-4-STAT6 signaling is 
able to attenuate the inflammatory response of macrophages through selective, direct 
repression of a distinct LPS-activated enhancer set. 
 
IL-4-mediated repression of inflammatory response results in attenuated 
inflammasome activation, decreased IL-1 production and pyroptosis 
 
Genes showing antagonistic regulation by IL-4 and LPS were mostly associated with 
inflammation-associated pathways, including NOD-like and Toll-like receptor signaling 
(Figure S5E). It is known that NOD-like receptors are required for inflammasome 
activation leading to IL-1 secretion and inflammasome-associated cell death, 
pyroptosis (Rathinam and Fitzgerald, 2016). As shown above, IL-4-STAT6 was able to 
reduce the basal and LPS-induced expression of a key inflammasome component, 
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Nlrp3 (Figure 1C, Figure 5D). Therefore, we investigated whether IL-4-STAT6 
signaling is able to influence IL-1ȕ production and pyroptosis. First, we examined the 
transcriptional regulation of Il1b expression in IL-4-pretreated and LPS-activated 
BMDMs. Reduced basal and LPS-induced RNAPII-pS2 and RNAPII-pS5 binding at 
Il1b gene body as well as Il1b mRNA expression were found in IL-4-pretreated BMDMs 
(Figure 7A and B). Moreover, Il1b_-9.7Kb enhancer located within the predicted 
subTAD of Il1b showed antagonistic regulation by LPS and IL-4 (Figure 7A), 
Intriguingly, LPS-induced p65-binding at the STAT6-bound Il1b_-9.7Kb enhancer (in 
case of one out of two p65 peaks) was partially attenuated by IL-4-STAT6 signaling 
pathway similarly to Fcgr1_-7.7Kb and IL-18_+25Kb enhancers described above 
(Figure 7A and C). Accordingly, IL-4-dependent repression of basal and LPS-induced 
eRNA expression was observed at the Il1b_-9.7Kb enhancer (Figure 7D). The IL-4-
dependent repression of basal and LPS-induced Il1b mRNA and eRNA expression 
were completely abolished in the absence of STAT6 (Figure 7B and D). LPS-induced 
NLRP3 and pro-IL-1ȕ expression were also attenuated at the protein level by IL-4-
STAT6 signaling (Figure 7E and Figure S7A), while the expression of other 
inflammasome components including proCaspase-1 and ASC was not altered 
following IL-4 and LPS stimulation of BMDMs (Figure 7E and Figure S7A).  
In order to determine whether IL-4-dependent repression of Nlrp3 expression is 
associated with decreased inflammasome activity, we analyzed the LPS and ATP-
induced caspase-1 activity in IL-4 pretreated and unstimulated mouse BMDMs using 
laser scanning cytometry. As expected, caspase-1 activation in WT BMDMs was 
induced dramatically by LPS and ATP costimulation (Figure 7F). Interestingly, LPS and 
ATP-induced caspase-1 activity was reduced significantly following 24 hours of IL-4 
pretreatment, which was completely dependent on STAT6 (Figure 7F). To assess the 
functional consequence of IL-4-STAT6-dependent reduction of inflammasome 
activation, we measured the secretion of IL-1ȕ in the presence of LPS and ATP in IL-
4-pretreated and untreated WT and Stat6-/- BMDMs. IL-1ȕ secretion was induced 
dramatically in WT and Stat6-/- BMDMs following LPS treatment (Figure 7G). However, 
LPS-dependent induction of IL-1ȕ secretion was partially inhibited by IL-4 pretreatment 
in a STAT6-dependent manner (Figure 7G). Next, we investigated the role of IL-4-
STAT6 signaling pathway in inflammasome activation-induced macrophage cell death, 
pyroptosis. A hallmark of pyroptosis is the insertion of pores into the plasma membrane 
 16 
that can be detected via LDH activity measurement from BMDM supernatants and 
propidium iodide (PI) staining. IL-4-pretreatment was able to effectively inhibit both 
LPS-induced LDH release and PI uptake in WT, but not in Stat6-/- BMDMs (Figure 7H 
and I).  
Finally, we determined whether the inflammatory responsiveness of Nlrp3 and Il1b 
genes is influenced in vivo by nematode infection-triggered alternative macrophage 
activation. Thus, we infected mice with Heligmosomoides polygyrus (H. polygyrus) and 
injected LPS or Salmonella Typhimurium into the peritoneal cavity 9 days after 
nematode infection. As expected, the number of the M2 macrophage marker Ym1 
positive macrophages was highly induced in peritoneal macrophages of H. polygyrus-
infected mice, confirming alternative macrophage activation following nematode 
infection (Figure S7B) (Ruckerl et al., 2017). In addition, inflammatory marker NOS2 
positive macrophage number was dramatically elevated in control and H. polygyrus-
infected mice following LPS injection or Salmonella Typhimurium infection showing the 
emergence of infection (Figure S7B). Although, Nlrp3 was not induced in the applied 
experimental system by LPS injection or Salmonella Typhimurium infection, steady-
state expression was significantly inhibited by H. polygyrus infection, and the inhibitory 
effect of nematode infection was sustained in the presence of inflammatory stimuli 
(Figure 7J). Nematode infection did not result in Il1b expression by peritoneal 
macrophages but both LPS injection and Salmonella Typhimurium infection resulted 
in a robust induction of Il1b expression. This elevated expression was significantly 
diminished in macrophages from H. polygyrus-infected mice (Figure 7J). 
These results suggest that prior in vitro or in vivo alternative macrophage polarization 
are able to restrain the subsequent inflammatory response of macrophages, including 
inflammasome activation, IL-1ȕ secretion as well as pyroptosis due to direct repression 
of Nlrp3 and Il1b gene expression by IL-4-STAT6 signaling. 
 
Discussion 
We unraveled an unsuspected repressor activity of the macrophage polarizing 
transcription factor, STAT6. We identified the target enhancers of “repressor” STAT6, 
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as well as the major components of the repressive mechanisms and its biological 
consequences. 
Macrophages exhibit great functional diversity and the ability to undergo rapid 
reprogramming depending on the changing molecular milieu in physiological and 
pathological conditions (Mosser and Edwards, 2008; Ruckerl et al., 2017). The 
epigenomic and molecular mechanisms of transcriptional activation by inflammatory 
mediators, cytokines and lipids have been intensively studied in macrophages (For a 
review see (Glass and Natoli, 2016)). In contrast, the mechanistic background of 
macrophage polarization signal-mediated transcriptional repression is less 
understood, though LPS-reduced nascent RNA expression was described (Bhatt et al., 
2012). In addition, LPS and TNFα-dependent reduction of enhancer activity was also 
observed in macrophages and adipocytes in the absence of inflammation activated 
NFkB-p65 binding (Hah et al., 2015; Schmidt et al., 2015). In contrast, we show that 
the IL-4-STAT6 signaling pathway represses a significant portion of macrophage 
transcriptome via STAT6-bound enhancers providing evidence that direct 
transcriptional repression also occurs during alternative macrophage polarization. 
Although the global transcriptional repressor activity of the key TFs for macrophage 
polarization (NF-κB, AP-1 and STATs) is not fully understood, several other SDTFs 
have been shown to possess distinct repressor activities. Ligand-activated nuclear 
receptors including PPARs and LXRs are able to reduce the activity of inflammatory 
SDTFs through transrepression carried out by direct protein-protein interactions 
without direct DNA binding (Glass and Saijo, 2010). It has also been described that a 
specific NF-κB-binding motif is present in the promoter regions of tolerogenic 
inflammatory genes regulating LPS tolerance via recruitment of the p50-NCoR-HDAC3 
repressosome (Yan et al., 2012). Our findings show that repressed enhancers exhibit 
lower STAT6 occupancy and underrepresented STAT6 de novo motifs compared to 
activated enhancers. These observations suggest that STAT6 acts as a transcriptional 
repressor either (i) without direct DNA binding or (ii) by recognizing non-canonical 
STAT6-binding motifs. It remains to be identified which mechanism is at play and, if 
STAT6 binding to the DNA is indirect, which DNA-bound factor interacts with STAT6. 
Our motif analysis suggests that the lineage-determining factors (PU.1 and C/EBPα) 
are the most likely candidates though PU.1 and C/EBPα binding also decreased at 
STAT6-repressed enhancers. Thus this requires further investigations. 
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STAT6-mediated repression appears to be distinct from other repressive mechanisms. 
Histone acetylation and gene expression tightly depends on the cofactor composition 
(HAT:HDAC ratio) (Calo and Wysocka, 2013). Several findings show the extensive 
participation of co-repressor proteins and HDACs in the inhibition of transcriptional 
activation by cytokine-activated STAT proteins (Icardi et al., 2012). However, the 
molecular mechanisms of STAT6-mediated direct transcriptional repression following 
IL-4 activation have not been described. Our cistromic studies show diminished p300 
binding at STAT6-repressed enhancers in IL-4-exposed macrophages, suggesting that 
reduced p300 binding is likely to be a key mechanism in the IL-4-STAT6 signaling 
pathway-mediated transcriptional repression. In addition, STAT6-repressed enhancers 
were occupied by HDAC1, 2 and 3, though their binding was not altered following IL-4 
stimulation. Nevertheless, our findings show evidence for the participation of NCoR-
HDAC3 corepressor complex in the IL-4-STAT6-induced transcriptional repression in 
a distinct subset of IL-4-repressed genes. Our data suggest that either the changed 
equilibrium between HATs and HDACs or perhaps the activity of HDAC3 that are 
regulated upon IL-4 stimulus. Potential mechanisms for the latter include 
posttranslational modifications or allosteric regulation. The mechanisms of non-
HDAC3-dependent repression also remain to be identified. 
Alternatively polarized macrophages are required for effective protection against 
different nematode infections reducing parasite number and inhibiting nematode-
induced tissue damage (Allen and Sutherland, 2014). However, nematode infection-
induced Th2-type inflammation can also influence the immune response against other 
pathogens and the prevalence of autoimmune or inflammatory diseases (Elliott and 
Weinstock, 2012; Ruckerl et al., 2017). Therefore, a better understanding of the 
potential interactions between Th2 and Th1-type inflammation-activated signaling 
pathways has a great importance in macrophage biology and also in immune-
inflammatory pathologies. It has been recently published that the IL-4-STAT6 signaling 
pathway can partially suppress IFNȖ-induced transcriptional program in macrophages 
following IL-4 and INFȖ co-treatment (Piccolo et al., 2017). However, our findings 
provide evidence that IL-4-STAT6 signaling pathway induces epigenetic changes that 
persist following the release of STAT6 from the DNA, leading to attenuated activation 
of inflammatory enhancers. The consequence of IL-4 priming-induced repression of 
inflammatory enhancers is the decreased responsiveness to inflammatory signals via 
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diminished basal and LPS-induced expression of several components of Toll-like and 
Nod-like receptor signaling pathways. In addition, the majority of IL-4-STAT6-
repressed genes show diminished expression in macrophages derived from Brugia 
malayii-implanted mice compared to thioglycollate-elicited macrophages. This formally 
suggests that alternative polarization likely induces partial desensitization of 
macrophages to further inflammatory signals in vivo. Accordingly, M2-type 
macrophages have been shown to protect mice against chemically-induced colitis and 
a growing body of evidence indicates that clinically controlled helminth infection is able 
to ameliorate inflammatory bowel disease (IBD) (Weinstock and Elliott, 2013). 
These studies suggest that complex bidirectional interactions exist between different 
polarization signals that determine the overall sensitivity and responsiveness of 
macrophages towards environmental stimuli. Our findings provide insights into this 
cross-talk at the level of individual enhancers and raise the intriguing possibility that IL-
4-STAT6 signaling, through direct transcriptional repression of inflammatory 
enhancers, induces desensitization of macrophages to microbial, stress and damage-
associated endogenous signals. 
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Figure legends: 
 
Figure 1. The IL-4-STAT6 signaling pathway induced gene expression during 
mouse alternative macrophage polarization. (A) Heat map of IL-4-regulated (p-
value≤0.05, FC≥β) gene expression clusters in WT murine BMDMs. Data represent 
the average fold changes of four individual animals. (B) The average fold change from 
the IL-4-repressed gene cluster at the indicated time points following IL-4 stimulation 
in WT (n=4) and Stat6-/- (n=2) BMDMs. Error bars represent means ±SD. (C) RT-qPCR 
analysis of gene expression on a set of IL-4-repressed genes in WT and Stat6-/- 
BMDMs. BMDMs were treated with IL-4 for 6 hours. Data are representative of five 
individual animals per genotype from two independent experiments. *P˂0.05, 
**P˂0.01, ***P˂0.001, ns. indicates not significant change. Error bars represent means 
±SD. (D) GSEA analysis of IL-4-repressed genes (in vitro) against a ranked list of 
genes regulated in the Brugia malayi-implanted mice-derived macrophages (Ne-Mac) 
compared to the intraperitoneal thioglycollate-administrated mice-derived peritoneal 
macrophages (Thio-Mac). (E) Expression of IL-4-repressed genes in the Brugia 
malayi-implanted mice-derived macrophages (Ne-Mac) and the intraperitoneal 
thioglycollate-administrated mice-derived peritoneal macrophages (Thio-Mac). Reads 
per kilobase per million values (RPKM) are presented as the mean and SD of three 
individual animals per group quantified by RNA-seq. *P˂0.05, **P˂0.01, ***P˂0.001. 
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Figure 2. Changes in RNAPII and H3K27Ac enrichments as well as nascent RNA 
transcription are immediate early markers of IL-4-STAT6-regulated transcription. 
(A) Metagene plot of RNAPII-pS5, RNAPII-pS2 and H3K27Ac-specific ChIP-seq 
enrichments and GRO-seq signals on the gene bodies of regulated gene clusters 
(Figure 1A) in the presence of IL-4 in WT BMDMs (TSS: transcription start site; TTS: 
transcription termination site). Coverage is defined as read count per million mapped 
reads. Data (H3K27Ac, RNAPII-pS2 and RNAPII-pS5) are combined from two 
independent biological replicates. (B) HγKβ7Ac, RNAPII-pS5 and RNAPII-pSβ ChIP-
seq signals at the selected IL-4-repressed gene bodies. ChIP-seq signals are 
visualized by the Integrative Genomics Viewer. Data are representative of two 
independent biological replicates. BMDMs in (A-B) were treated with IL-4 for 1 hour. 
 
Figure 3. RNAPII-pS5-based characterization of IL-4-activated STAT6 cistrome in 
mouse macrophages. (A) Histograms of the average coverage of STAT6 peaks at 
the indicated period of time following IL-4 treatment in WT BMDMs. (B) Pie chart of the 
RNAPII-pS5 positive and negative STAT6-bound regulatory regions, 1 hour of IL-4 
stimulation. (C) Read distribution plot of ChIP-seq intensities for STAT6 and RNAPII-
pS5 around the summit of the detected STAT6 peaks in a 4kb window (left). Clustering 
of STAT6-RNAPII-pS5 co-bound genomic regions was based on the usage of DiffBind 
analysis (p≤0.05). Box plots of the average RPKM values for RNAPII-pS5 in each 
cluster (right). Boxes encompass the 25th to 75th percentile RPKMs. Whiskers extend 
to the 10th and 90th percentiles. (D) Box plots of RNAPII-pS2 and H3K27Ac read 
enrichments (RPKM) around the identified STAT6 peak clusters in WT BMDMs. Boxes 
encompass the 25th to 75th percentile RPKMs. Whiskers extend to the 10th and 90th 
percentiles. (E) Heat map of correlations between STAT6 peak (Figure 3C) and IL-4-
regulated gene clusters (Figure 1A) based on genomic proximity and functional 
chromatin domain prediction. (F) Integrative Genomics Viewer snapshots of STAT6, 
H3K27Ac, RNAPII-pS5 and RNAPII-pS2 ChIP-seq signals on a set of IL-4-repressed 
and activated genomic loci. (G) RT-qPCR measurements of eRNA expression at IL-4-
repressed enhancers in WT and Stat6-/- macrophages. (H) Bar plots showing the 
percentage of the STAT6 motif positive STAT6 peaks in the clusters on panel C. The 
STAT6 binding motif was used for targeted search. Dashed line indicates background 
(Bg: 9.51%). (I) Box plot of STAT6 motif scores at the functionally distinct STAT6 peak 
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clusters. Boxes encompass the 25th to 75th percentile motif scores. Whiskers extend 
to the 10th and 90th percentiles. 
BMDMs in (B-D, F and G) were treated with IL-4 for 1 hour. Data in (A-D) are combined 
from two independent biological replicates. Changes in (D) were considered significant 
at p<0.00001 using paired t-test and an average fold change cut off value of ≥1.15 was 
used between ctrl and IL-4-treated samples. # means significant difference, n.s. 
indicates not significant change. Data in (F) are representative of two independent 
biological replicates. Data in (G) are representative of five individual animals per 
genotype from two independent experiments. *P˂0.05, **P˂0.01, ***P˂0.001, ns. 
indicates not significant change. Error bars represent means ±SD. 
 
Figure 4. IL-4-induced changes at repressor and activator STAT6 sites and the 
role of HDAC3 in IL-4-STAT6-mediated repression. (A) Box plots of ATAC-seq and 
(B, C, and D) ChIP-seq signals for PU.1, p300, HDAC1, HDAC2 and HDAC3 on the 
repressor and activator STAT6 sites in WT BMDMs. Boxes encompass the 25th to 
75th percentile RPKMs. Whiskers extend to the 10th and 90th percentiles. (E) Box 
plots of the expression of IL-4-HDAC3-dependent repressed genes in WT (n=3) and 
HDAC3fl/fl Lyz2 Cre (n=3) BMDMs using publicly available microarray results. Boxes 
encompass the 25th to 75th percentile changes. Whiskers extend to the 10th and 90th 
percentiles. (F) Metagene plots of RNAPII-pS5 and RNAPII-pS2 signals at the gene 
bodies of IL-4-HDAC3-dependent repressed genes. Coverage is defined as read count 
per million mapped reads. (G) Read distribution plot of ChIP-seq intensities for RNAPII-
pS5, STAT6, HDAC3, NCoR and SMRT around the summit of the detected STAT6 
peaks at the IL-4-repressed enhancers (n=325) in the subTADs of HDAC3-dependent 
repressed genes, 1 hour of IL-4 stimulation. (H) Box plot of the average HDAC3 binding 
intensity on the genomic regions (panel G). Boxes encompass the 25th to 75th 
percentile RPKMs. Whiskers extend to the 10th and 90th percentiles. (I) Normalized 
microarray signal intensity of Fos, Lyz1, Lyz2 and Smad3 genes in control or IL-4-
stimulated WT and HDAC3fl/fl Lyz2 Cre BMDMs. (J) RT-qPCR measurements of Fos, 
Lyz1, Lyz2 and Smad3 expression in control or IL-4 stimulated WT and NCoRfl/fl 
iBMDMs. 
BMDMs were treated with IL-4 for 1 hour in (A-D, F, G and H) or 24 hours in (E, I and 
J). Data in (A-D, F and H) are combined from two independent biological replicates. 
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Changes in (A-D and H) were considered significant at p<0.00001 using paired t-test 
and an average fold change cut off value of ≥1.15 was used between ctrl and IL-4-
treated samples. # means significant difference, ns. indicates not significant change. 
Data in (I) represent the mean and SD of three independent biological replicates. 
*P˂0.05, **P˂0.01, ***P˂0.001, ns. indicates no significant difference. Error bars 
represent means ±SD. Data in (J) represent the mean and SD of three independent 
biological replicates. *P˂0.05, **P˂0.01, ***P˂0.001, ns. indicates no significant 
difference. Error bars represent means ±SD. 
 
Figure 5. Selective repression of LPS-activated inflammatory program by IL-4-
activated STAT6. (A) Schematic representation of the experimental system. (B) Box 
plot of the fold changes of LPS-activated genes (RNA-seq). Clustering was based on 
the different LPS-induced gene expression effects on IL-4-pretreated and untreated 
BMDMs (p˂0.05). Data represent the average fold changes of three individual animals 
from two independent experiments. Boxes encompass the 25th to 75th percentile 
changes. Whiskers extend to the 10th and 90th percentiles.  (C) Metagene plot of 
RNAPII-pS2 signals over the gene bodies of the genes in the clusters (panel B). 
Coverage is defined as read count per million mapped reads. Data are combined from 
two independent biological replicates. (D) RT-qPCR measurements of basal and LPS-
induced expression of the inflammation-associated genes in IL-4-pretreated and 
unstimulated WT and Stat6-/- BMDMs. Data are cumulative of four individual animals 
per genotype from two independent experiments. *P˂0.05, **P˂0.01, ***P˂0.001, n.s. 
indicates no significant difference. Error bars represent means ±SD. 
BMDMs were pretreated with IL-4 for 24 hours followed by LPS exposure for 3 hours 
in (B and D) or 1 hour in (C). 
 
Figure 6. Attenuated inflammatory response is conferred by the repressive 
action of IL-4-STAT6 signaling on a subset of enhancers. (A) Venn-diagram of the 
overlap between the STAT6-bound regulatory regions associated to IL-4-inhibited 
LPS-responsive genes and the LPS-activated p65 cistrome. (B) Flowchart of the 
identification of IL-4-repressed, LPS-inducible inflammatory enhancers. Significant 
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changes in RNAPII binding were identified by DiffBind analysis (p≤0.05). (C) Read 
distribution plot of ChIP-seq intensities for RNAPII-pS5 and RNAPII-pS2 around the 
summit of STAT6 peaks on the identified 448 overlapping STAT6 and p65-bound 
regulatory elements exhibiting IL-4-dependent attenuation of LPS response. (D) Box 
plot of the average coverage (RPKM) for RNAPII-pS5 and RNAPII-pS2 binding at the 
regulatory regions presented on the read distribution plot on panel C, exhibiting 
attenuated LPS response in IL-4-pretreated BMDMs. Boxes encompass the 25th to 
75th percentile RPKMs. Whiskers extend to the 10th and 90th percentiles. (E) Box plot 
of the average coverage (RPKM) for p65 binding at the regulatory regions presented 
on the read distribution plot on panel C, exhibiting attenuated LPS response in IL-4-
pretreated BMDMs. Regulatory regions showing repressed (left) and not influenced 
(right) p65 binding are shown. Boxes encompass the 25th to 75th percentile RPKMs. 
Whiskers extend to the 10th and 90th percentiles. (F) Genome browser views of the 
IL-4 repressed regulatory regions showing attenuated LPS response in IL-4-pretreated 
BMDMs. ChIP-seq signals for RNAPII-pS5, RNAPII-pSβ and p65 are shown.  
BMDMs were pretreated with IL-4 for 24 hours followed by 1 hour LPS exposure in (A-
E). Data in (A-E) are combined from two independent biological replicates. Changes 
in (D-E) were considered significant at p<0.00001 using paired t-test and an average 
fold change cut off value of ≥1.15 was used between ctrl and IL-4-treated samples. # 
means significant difference, ns. indicates not significant difference. Data in (F) are 
representative of two independent biological replicates. 
 
Figure 7. IL-4 pretreatment dampens the inflammatory response of 
macrophages, incuding inflammasome activation, IL-1β production and 
pyroptosis. (A) Genome browser view of STAT6, RNAPII-pS5, RNAPII-pS2 and p65-
specific ChIP-seq signals on the Il1b locus. Data are representative of two independent 
biological replicates. (B) RT-qPCR-based measurement of basal and LPS-induced Il1b 
expression in IL-4-pretreated and unstimulated WT and Stat6-/- BMDMs. Data are 
cumulative of four individual animals per genotype from two independent experiments. 
*P˂0.05, **P˂0.01, ***P˂0.001, ns. indicates no significant change. Error bars 
represent means ±SD. (C) ChIP-qPCR measurement of p65 binding at IL-1ȕ_-9.7Kb 
enhancer from WT and Stat6-/- BMDMs. Data represent the mean and SD of two 
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biological replicates. +P˂0.1, ns. indicates not significant change. (D) RT-qPCR- 
measurement of basal and LPS-induced IL-1ȕ_-9.7Kb eRNA expression in IL-4-
pretreated and unstimulated WT and Stat6-/- BMDMs. Data are cumulative of four 
individual animals per genotype from two independent experiments. *P˂0.05, 
**P˂0.01, ***P˂0.001, ns. indicates not significant change. Error bars represent means 
±SD. (E) Western blot determination of basal and LPS-regulated Nlrp3, pro-IL-1ȕ, pro-
Caspase1, ASC and ȕ-actin expression in IL-4-pretreated and unstimulated WT and 
Stat6-/- BMDMs. Data are representative of five individual animals per genotype from 
two independent experiments. (F) Contour map representation of laser-scanning 
imaging cytometry of Caspase-1 activity in WT and Stat6-/- BMDMs. Data are 
representative of two independent experiments. (G) ELISA measurement of IL-1ȕ 
secretion in IL-4-pretreated and unstimulated WT and Stat6-/- mouse BMDMs. Data 
represent the mean and SD of three individual animals. *P˂0.05, **P˂0.01, ***P˂0.001, 
ns. indicates no significant change. (H) Lactate dehydrogenase activity assay 
measurement of LPS and ATP co-stimulation-induced LDH release in IL-4-pretreated 
and unstimulated WT and Stat6-/- BMDM supernatants. LDH release expressed as the 
percentage of Triton X-100-liberated total LDH release. Data represent the mean and 
SD of three individual animals. *P˂0.05, **P˂0.01, ***P˂0.001, ns. indicates no 
significant change. (I) Contour map representation of laser-scanning imaging 
cytometry analysis of PI-labelled WT and Stat6-/- BMDMs. Data are representative of 
two independent experiments. (J) Basal, LPS and Salmonella Typhimurium (SL3261)-
induced expression of Nlrp3 and Il-1ȕ expression in naïve and Heligmosomoides 
polygyrus (H. polygyrus)-infected mice-derived peritoneal macrophages. Each data 
point represents the mean and SD of five-six individual animals per group. *P˂0.05, 
**P˂0.01, ***P˂0.001, ns. indicates no significant change. 
BMDMs were pretreated with IL-4 for 24 hours followed by LPS exposure for 1 hour in 
(A and C), 3 hours in (B, D, E, F. H and I) or the indicated period in (G). 
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STAR Methods 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be fulfilled 
by the lead contact, Laszlo Nagy (lnagy@sbpdiscovery.org). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Mice 
All strains are on C57BL/6 genetic background. Stat6−/− is a full body knockout and it was purchased 
from The Jackson Laboratory. Animals were housed under minimal disease conditions and the 
experiments were carried out under institutional ethical guidelines and licenses. 
 
Bone Marrow-Derived Macrophages 
Isolation and differentiation were completed as described earlier (Daniel et al., 2014). Isolated bone 
marrow-derived cells were differentiated for 6 days in the presence of L929 supernatant. Differentiated 
BMDMs were treated with IL-4 (20 ng/ml), LPS (100 nM) and ATP (5mM) for the indicated period of 
time.  
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Immortalization of mouse bone marrow-derived macrophages 
Bone marrow-derived cells were immortalized using the J2 cell line continuously producing the J2 virus 
encoding v-raf and v-myc oncogenes (Gandino and Varesio, 1990). J2 cells were grown in DMEM 
containing 20% FBS. Bone marrow cells were seeded in immortalization media I. (90% J2 supernatant, 
5% HyClone FBS, 10ug/ml Polybrene 0.1%, L929 supernatant 5%) and incubated overnight. On the 
second day supernatant was collected and spun down to pellet floating cells. Adherent cells were 
scraped and re-plated in a new petri dish using immortalization media II. (20% J2 supernatant, 10% 
HyClone FBS, 10ug/ml Polybrene 0.1%, L929 supernatant 10%, 60% DMEM) and incubated for 6 days. 
After the immortalization cells were kept in regular macrophage differentiation media (20% FBS, 30% 
L929 supernatant and 50% DMEM containing 1% antibiotics). 
 
METHOD DETAILS 
 
RNA-seq 
cDNA library for RNA-Seq was generated from 1g total RNA using TruSeq RNA Sample Preparation 
Kit (Illumina, San Diego, CA, USA) according to the manufacturer’s protocol. Briefly, poly-A tailed RNAs 
were purified by oligodT conjugated magnetic beads and fragmented on 94 C degree for 8 minutes, 
then 1st strand cDNA was transcribed using random primers and SuperScript II reverse transcriptase 
(Lifetechnologies, Carslbad, CA, USA). Following this step second strand cDNA synthesized, double 
stranded cDNA end repaired and γ’ ends adenylated then Illumina index adapters were ligated. After 
adapter ligation enrichment PCR was performed to amplify adapter ligated cDNA fragments. Fragment 
size distribution and molarity of libraries were checked on Agilent BioAnalyzer DNA1000 chip (Agilent 
Technologies, Santa Clara, CA, USA). Paired read 100bp sequencing runs were performed on Illumina 
HiScan SQ instrument (Illumina, San Diego, CA, USA). 
 
ChIP-seq and ChIP-qPCR 
ChIP was performed essentially as previously described (Daniel et al., 2014). Libraries were prepared 
either with Ovation Ultralow Library Systems (Nugen) or TruSeq ChIP library systems (Illumina) 
according to the manufacturer’s instructions. The following antibodies were used: H3K27Ac (ab4729), 
P300 (sc-585), PU.1 (sc-352), JunB (sc-46x), IRF8 (sc-32528x), STAT6 (sc-981), C/EBPα (sc-61X), 
HDAC1 (ab7028), HDAC2 (ab7029), HDAC3 (ab4729), RNA PolII-pS5 (ab5131) and RNA PolII-pS2 
(ab5095), p65 (sc-372). Primer sequences for ChIP-qPCR are available in Supplemental Table 6. 
 
ATAC-seq 
ATAC-seq was carried out as described earlier with minor modification (Buenrostro et al., 2013). Cells 
were scraped and counted to achieve 50k/ml in ice-cold PBS. Cell suspension was further diluted to 
25k/ml and nuclei were isolated with ATAC-LB (10mM Tris-HCl pH7.4, 10mM NaCl, 3mM MgCl2, 0.1% 
IGEPAL). Nuclei from 25k cells were used for tagmentation using Nextera DNA Library Preparation Kit 
(Illumina) from two biological replicates. After tagmentation DNA was purified with Minelute PCR 
Purification Kit (Qiagen). Tagmented DNA was amplified with Kapa Hifi Hot Start Kit (Kapa Biosystems) 
using 9 PCR cycle. Amplified libraries were purified again with Minelute PCR Purification Kit. Fragment 
distribution of libraries was assessed with Agilent Bioanalyzer and libraries were sequenced on a HiSeq 
2500 platform. 
 
GRO-seq 
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GRO-seq was performed as described earlier (Daniel et al., 2014), but the libraries were prepared with 
NEBNext Small RNA Library Prep set for Illumina. 
 
Real-Time Quantitative PCR for enhancer RNA and mRNA detection (qPCR) 
RNA was isolated with Trizol reagent (Ambion). RNA was reverse transcribed with High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) according to manufacturer’s protocol. Transcript 
quantification was performed by qPCR reactions using SYBR green master mix (BioRad). Transcript 
levels were normalized to Ppia. Primer sequences are available in Supplemental Table 6. 
 
LDH release 
LDH activity was measured in the supernatants of unstimulated and IL-4-pretreated WT and STAT6KO 
bone marrow-derived macrophages after IL-4 pretreatment and/or LPS/ATP costimulation (LPS-
exposed BMDMs were treated with ATP for 30 min) by commercially available LDH UV assay on Cobas 
c 501 instrument (Roche Diagnostics, Mannheim, Germany). This measurement is based on the 
conversion of L-lactate to pyruvate along with the reduction of NAD+ to NADH. The initial rate of the 
NADH formation was directly proportional to the catalytic LDH activity determined by photometrically 
measuring the absorbance increment at 340 nm. 
 
Measurement of IL-1β production 
LPS-exposed BMDMs were treated with ATP for 45 min. Supernatants from ATP-treated macrophages 
were collected, centrifuged and stored at -20 oC until further use. IL-1ȕ was measured from samples 
using ELISA kit (DY401-05, R&D System) according to the manufacturer’s instructions and analyzed on 
FlexStation 3 Microplate Reader (Molecular Devices). The minimum detectable dose is 15.6 pg/ml. 
 
Western Blot analysis 
Cells were harvested and centrifuged, then they were lysed in loading buffer (62,5mM Tris pH=8.8, 25% 
glycerol, 2% SDS, 1% ȕ-mercaptoethanol and 1% BPB). Before loading all samples were boiled for 10 
minutes. Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes. 
Membranes were then blocked with 5% non-fat milk, washed briefly, incubated with primary antibodies 
at 4°C overnight. Pro-IL-1ȕ (AF401-NA) was from R&D System, ASC (sc22514-R) was from Santa Cruz, 
pro-caspase-1 (AG-20B-0042) and NLRP3 (AG-20B-0014) antibodies were obtained from AdipoGen. 
Primary antibodies were incubated with corresponding horseradish peroxidase-conjugated secondary 
antibodies from BioRad for 1 hour at room temperature. Proteins were visualized by Supersignal West-
Pico peroxide/luminol enhancer solution from Pierce. To verify the loading of equal amount of protein 
sample, the ȕ-actin (Sigma-Aldrich) expression was detected. 
 
Laser Scanning Cytometry 
Caspase-1 activity and pyroptotic cell death by propidium iodine staining was measured in single cells 
using imaging Laser Scanning Cytometry (LSC). Mouse macrophages were cultured, treated, stained 
and imaged in 8 well IBIDI (Martinsried, Germany) slides with an initial concentration of 15,000 cells per 
well. Sub-vital staining was performed in culture medium at room temperature for 20 minutes by Hoechst 
34580 (10 microg/ml), propidium iodine (10 microg/ml), Alexa-488 tagged Annexin V (1 microg/ml) and 
caspase-1 specific FLICA® 660 (FLICA® 660 far-red fluorescence Caspase-1 Assay Kit was used 
according to the description of manufacturer; ImmunoChemistry Technologies, LLC). In some 
experiments specific Caspase-1/ICE Inhibitor Z-WEHD-FMK (R&D Systems, Inc. Minneapolis, MN, 
USA) was also used before FLICA labeling. For LSC imaging an iCys Research Cytometer (formerly 
CompuCyte; Thorlabs Imaging Systems, Sterling, VA) was used with its iNovator Application 
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Development Toolkit software. Hoechst, Alexa, PI and FLICA fluorescence dyes were excited separately 
with 405, 488, 488, 633 nm laser lines and detected at 430-470, 515-545, 650-700, 650 and above 
nanometers, respectively. Single cell data were gated according to their area, DNA content and nuclear 
shape and fluorescence pixel integral, maximum pixel intensity and average pixel intensity parameters 
with raw images were recorded for all dyes. For cytoplasmic caspase-1 activity measurements dynamic 
background subtraction was applied. Gated single cell FCS data were exported from LSC software and 
contour plots were generated in FCS Express 5 flow and image cytometry data analysis software (De 
Novo Software, Glendale, CA, USA). 
 
In vivo infection model 
Heligmosomoides polygyrus life cycle was maintained in house and infective third-stage larvae (Lγ) 
were obtained as described elsewhere (Johnston et al., 2015). Mice were infected with 200 H polygyrus 
L3 by oral gavage. The attenuated, aroA deficient Salmonella enterica enterica serovar Typhimurium 
strain SL3261 (Hoiseth and Stocker, 1981) was cultured as stationary overnight culture from frozen 
stock in Luria-Bertani broth. Co-infections were carried out as described previously (Ruckerl et al., 
2017). Briefly, animals were injected i.p. with ~1x10^6 CFU Salmonella Typhimurium diluted in PBS or 
received 1 mg/kg LPS from Salmonella enterica ser. Minnesota (Sigma Aldrich L4641) 9 days after 
H.polygyrus infection. 6h after bacterial inoculation peritoneal macrophages were isolated by lavage, 
purified by adherence for 2 h to cell culture plastic and total RNA extracted. 
 
Flow cytometry 
All antibodies were purchased from Biolegend UK unless otherwise indicated. Equal numbers of cells 
were stained with LIVE/DEAD cell viability assay (Life Technologies) and blocked with 5 μg/mL anti- 
CD16/γβ (β.4Gβ, BD Biosciences) and heat-inactivated normal mouse serum (1:10) in FACS buffer 
(0.5% BSA and β mM EDTA in Dulbecco’s PBS) before surface staining with antibodies to F4/80 (BM8), 
Siglec-F (E50-β440), Ly-6C (HK1.4), Ly-6G (1A8), TCRȕ (H57-597), CD11b (M1/70), CD11c (N418), I-
A/I-E (M5/114.15.2), CD19 (6D5) and CD115 (AFS98). Detection of intracellular Ym1 and NOS2 was 
performed directly ex vivo. Cells were stained for surface markers then fixed with 2% paraformaldehyde 
(Sigma Aldrich), permeabilized using Permeabilization Buffer (eBioscience) and stained with directly 
labeled antibodies to NOS2 (CXNFT; eBioscience) or biotinylated polyclonal goat anti-Ym1 (R&D 
Systems) followed by streptavidin-PerCP (Biolegend). Expression of Ym1 and NOS2 was determined 
relative to appropriate polyclonal or monoclonal isotype controls. 
Samples were acquired on a BD LSR II using BD FACSDiva software (BD Bioscience) and post-
acquisition analysis performed using FlowJo v9 software (Tree Star Inc.). Macrophages were identified 
as lineage negative (CD19-,TCRb-,Ly6G-,SiglecF-), CD11b+ CD115+. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
RNA-seq analysis 
TopHat and Cufflinks toolkits (Trapnell et al., 2013) were used for mapping spliced reads to the mm10 
mouse assembly with default parameters, making transcript assemblies, and getting and sorting gene 
expression data. Genes with at least 1 FPKM (Fragments Per Kilobase per Million mapped reads) 
expression value in at least one sample were considered to be expressed. In the downstream analysis 
2-way anova and post-hoc tests were performed on WT and Stat6-/- macrophages exposed to IL-4 for 
1, 3, 6 and 24 hours in R using the aov() and TukeyHSD() functions of the MASS package. Differences 
were considered statistically significant at p-value<0.05 and FC>2. For IL-4 pretreatment-LPS datasets, 
LPS-induced genes were considered statistically significant at p-value<0.05 compared to the control 
and then these genes were clustered based on their sensitivity (p-value<0.05) to IL-4 pretreatment as 
follows: attenuated response - Cluster 1; insensitive - Cluster 2; increased response - Cluster 3. K-
means clustering was performed in R using the function kmeans from package stats. Gene Set 
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Enrichment Analysis was done by GSEA v2.2.0 (Subramanian et al., 2005). KEGG pathway enrichment 
analyses were done using the DAVID web application (Huang da et al., 2009). Heat maps were drawn 
using the R package pheatmap. 
 
ATAC-seq, ChIP-seq and GRO-seq analyses 
The primary analysis of the ATAC-seq, ChIP-seq and GRO-seq raw sequence reads was carried out 
using our ChIP-seq analysis command line pipeline (Barta, 2011). Briefly, Burrows-Wheeler Alignment 
Tool (BWA, (Li and Durbin, 2009)) was used to align the reads to mm10 genome assembly with default 
parameters. MACS2 (Zhang et al., 2008) (with ‘-B’ and ‘-SPMR’ options) was used for predicting 
transcription factor peaks and nucleosome free regions (q-value<=0.01), and findPeaks.pl (with ‘-size 
1000’, ‘-minDist β500’ and ‘-style histone’ options) for histone regions. Artifacts were removed using the 
ENCODE blacklist (Consortium, 2012). Predicted peaks were sorted by average coverage (RPKM, 
Reads Per Kilobase per Million mapped reads). Average coverage of the predicted peaks and 
significantly changing regions (p-value<=0.05) were calculated by DiffBind v2.0.5 (Ross-Innes et al., 
2012). Intersections, subtractions and merging of the predicted peaks were made with BedTools. 
Proportional Venn diagrams were generated with VennMaster (Kestler et al., 2008). Genome coverage 
files (bedgraph files) for visualization were generated by makeUCSCfile.pl (HOMER) and then converted 
into tdf files using igvtools with ‘toTDF’ option. De novo motif discovery was performed on the 100 bp 
vicinity of the peak summits using findMotifsGenome.pl with options ‘–len “10,1β,14,16”’ and ‘-size β00’ 
on the repeat-masked mouse genome (mm10r) from HOMER. The HOMER option ‘-style groseq’ was 
used for GRO-seq samples. Integrative Genomics Viewer (IGV2.3, Broad Institute) was used for data 
browsing (Thorvaldsdottir et al., 2013) and creating representative snapshots. Normalized tag counts 
for Meta histograms and RD plots were generated by annotatePeaks.pl from HOMER (with option ‘-hist 
10’ for histograms and with options ‘-ghist’ and ‘-hist 10’ for RD plots) and visualized by R using package 
ggplot2 or by Java TreeView, respectively. Gene body metaplots were created using ngs.plot software 
(Shen et al., 2014). Pearson’s correlation coefficients between GRO-seq, PolII S2, PolII S5 and 
H3K27ac ChIP-seq data (fold change of RPKM values upon 1h IL-4 treatment on the merged replicates 
using a custom bash script) were calculated in R using function cor() from package stats. Changes on 
boxplots were considered significant at p<0.00001 using paired t-test and the average of fold differences 
at the individual enhancers ≥1.15. 
 
Domain prediction 
ChIP-seq raw reads of 47 CTCF and 42 Cohesin (RAD21, SMC1/3 or SA1/2) samples were downloaded 
from the Sequence Read Archive of NCBI and processed using our ChIP-seq analysis command line 
pipeline (Barta, 2011). Consensus CTCF peak summits were defined as the average genomic location 
of at least two summits within 51 bp. Consensus peak summits for Cohesin were defined in the same 
manner. Insulator peak summits were determined from those consensus CTCF peak summits that were 
closer to a consensus Cohesin peak summit than 51 bp. Motif enrichments were calculated in two rounds 
by findMotifsGenome.pl (HOMER) from the 100 bp region around the 5000 most ubiquitous insulator 
peak summits. Having mapped the putative elements matching with the CTCF motif of the first search 
by annotatePeaks.pl (HOMER), we used those top 5000 regions that lacked these hits. Score 6 was set 
as a threshold for both CTCF motif matrices, and to filter putative CTCF elements in the case of multiple 
occurrences at the same region those hits were preferred that followed the direction of the 
CTCF/Cohesin peak location compared to each other (Rao et al., 2014) and had the highest motif score. 
Insulators showing clear protein-binding direction without predicted element were also included in 
domain prediction. Average coverage (RPKM) of CTCF and RAD21 ChIP-seq derived from bone 
marrow-derived macrophages was calculated on the 100 bp region around insulators, and those regions 
were filtered out that had an RPKM value exceeding the hundred-thousandth of the summed density of 
all regions per sample in both samples. The closest insulators showing convergent direction within 1Mb 
distance but farther than 1kb were assigned to each other and called domains if their coverage showed 
less than 2-fold difference for both proteins. In the case of overlapping domains, those were filtered 
having the highest insulator coverage. “Negative” domains with divergent insulators were defined 
between the final convergent domains. Association scores between STAT6-bound enhancers and IL-4-
regulated gene clusters were calculated and visualized by package pheatmap using option 
scale="column" (scaling by RNA-seq clusters). 
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Statistical analysis 
Statistical analysis for qRT-PCR, ChIP-qPCR, ELISA, LDH-release assay, FACS analysis and 
densitometry analysis of Western blot: the error bars represent standard deviation (SD). The two-tailed 
Student’s t test was used to evaluate the significance of differences between two groups. Quantification 
and alignments of NGS analysis for RNA-seq, ChIP-seq and ATAC-seq are also described in more 
detail in the methods section above. 
 
DATA AND SOFTWARE AVAILABILITY 
The accession number for the RNA-seq, ChIP-seq, GRO-seq and ATAC-seq data reported in this paper 
is GEO: GSE106706. Microarray and RNA-seq data sets were downloded from GEO database 
(GSE33609) and ArrayExpress (E-MTAB-995). ChIP-seq data sets were downloaded from GEO 
database (GSE27060 and GSE38379) as well as SRA database (SRP019970). The used genome-wide 
data sets are collected in Supplemental Table 7. 
 
Supplemental Table 1. The expression level of IL-4-STAT6 signaling pathway-
regulated genes in WT and STAT6-/- mouse BMDMs, Related to Figure 1. 
Supplemental Table 2. IL-4-regulated RNAPII-pS2-associated genes in WT mouse 
BMDMs, Related to Figure 2. 
Supplemental Table 3. RNAPII-pS5 positive STAT6-bound genomic regions in WT 
mouse BMDMs, Related to Figure 3.  
Supplemental Table 4. Genomic distribution, LDTF and cofactor binding positivity of 
RNAPII-pS5 positive STAT6 peak clusters, Related to Figure 3 and 4.  
Supplemental Table 5. The expression level of LPS-induced genes in IL-4-pretreated 
and control WT mouse BMDMs, Related to Figure 5. 
Supplemental Table 6. Primers for mRNA and eRNA expression as well as ChIP-
qPCR, Related to STAR Methods. 
Supplemental Table 7. The list of the applied RNA-seq, ChIP-seq, GRO-seq, ATAC-
seq and microarray data sets, Related to STAR Methods.   
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